Study of Image-guided Dosimetry for Interstitial Prostate Brachytherapy

Completed · Phase 1

Conditions studied: Locally Confined Adenocarcinoma of the Prostate

In brief

This will be a phase I study. This phase I study is not a standard drug dose escalation study, but rather a Clinical System Performance Evaluation Trial of a therapeutic device. However for purposes of this protocol we will refer to this portion of the trial as a phase I study. The purpose of this study is to demonstrate the feasibility and clinical practicability of the registered ultrasound and fluoroscopy (RUF) in combination with CMS Interplant system® in an initial cohort of 6 patients. This will involve demonstrating the feasibility of using the system in an actual operating room environment as well as obtaining a preliminary assessment of the accuracy and performance of the source location algorithm by comparing with postoperative CT dosimetry. The Primary endpoint of this study will be evaluation of the feasibility of using the RUF system and of performing real-time optimization in the operating room environment. The Secondary endpoints of this study will be: 1. Acute and late toxicity as assessed by IPSS, SHIM, and EPIC questionnaires at multiple follow-up intervals. 2. PSA-free survival. Study Population: The target population will be patients with a diagnosis of adenocarcinoma of the prostate who are seen in consultation at the Johns Hopkins Hospital. Approximately 360 patients per year with the diagnosis of prostate cancer are seen in the Department of Radiation Oncology at Johns Hopkins Hospital. Of these patients, approximately 45% have low-risk (T1a-T2a, Gleason 6 or less, PSA 10 ng/ml or less) or intermediate-risk disease and are suitable for brachytherapy based on disease risk. Within this group of patients, approximately 70% are eligible for brachytherapy based on gland size and no prior transurethral resection of prostate (TURP). Approximately 80% of patients offered brachytherapy at consultation decide to receive their treatment at Johns Hopkins. Overall, we currently perform 2 brachytherapy procedures per week on average, for a yearly total of approximately 90 cases. For purposes of homogeneity of treatment and patient population, this protocol will only enroll patients currently treated at this institution with brachytherapy alone, and will not enroll patients (intermediate or high risk disease) who will require external beam radiation in addition to brachytherapy.

Key facts

Study ID

NCT00426959

Run by

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

People needed

6

Starts

2005-02-01

Expected to finish

2010-04-01

Last updated by the study team

2012-11-14

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed, locally confined adenocarcinoma of the prostate
• PSA of less than 10 ngmL
• Combined Gleason score 6 or less, with no individual Gleason score of 4 or 5
• The patient has decided to undergo brachytherapy at the Johns Hopkins Hospital as treatment choice for his prostate cancer
• Karnofsky Performance Status greater than 70
• Prostate volume by TRUS less than 50 cc
• International Prostate symptom score must be 18 or less
• Signed study-specific consent form prior to registration

You may not qualify if…

• Clinical or Pathological Lymph node involvement,
• Evidence of distant metastases
• Radical surgery for carcinoma of the prostate
• Chemotherapy or pelvic radiation therapy
• Previous transurethral resection of the prostate
• Previous or concurrent cancers other than basal or squamous cell skin cancers unless disease free for at least 5 years.
• Significant obstructive symptoms
• Major medical or psychiatric illness which, in the investigator's opinion, Hip prosthesis
• Anatomic or medical condition (such as prior abdominal perineal resection or anal stricture) which would preclude the use of TRUS Implanted device or apparatus which might obstruct visibility of the implanted sources on fluoroscopy

Where it is running

• The Sidney Kimmel Comprehensive Cancer Center at The Johns Hopkins University — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.